The firm said in May it was considering the surcharge following disclosure of a $40 million tariff-related headwind for 2025.

Adding the firm's multi-cancer early detection test to standard-of-care screening demonstrated substantially greater additional cancer detection than in Pathfinder.

The shares are expected to begin trading on June 18 under the ticker symbol CAI, and the offering is expected to close on June 20.

Castle's first disease target is atopic dermatitis, with the goal to develop a test that can predict future flare-ups of the disease.

NEW YORK – Visby Medical announced Tuesday that it has raised about $55 million in a recent financing round with the total potentially reaching $65 million.

NEW YORK – Scope Biosciences has secured €1 million ($1.2 million) in follow-on investment to scale its molecular diagnostics platform. The diagnostics developer said Monday that the investment from ...

The acquisition is intended to expand the French firm's presence in sequencing-based infectious disease testing.

Last week, readers were most interested in a story about reports of a possible sale by Thermo Fisher Scientific of parts of its diagnostics business.

The Birmingham, UK, firm hopes to develop a broader test menu with industry partners, using AI and machine-learning approaches.

The company uses artificial intelligence to detect metabolic patterns from urine samples that indicate prostate cancer.

The University of Chicago spinout said that it will use the money to support the commercialization of its saliva-based sequencing test for oral cancers.